Apricus Biosciences, Inc (NASDAQ:APRI) will post its quarterly earnings results after the market closes on Wednesday, August 2nd. Analysts expect Apricus Biosciences to post earnings of ($0.16) per share for the quarter.

Apricus Biosciences (NASDAQ:APRI) last announced its earnings results on Thursday, May 11th. The company reported $1.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.25 by $0.21. During the same period last year, the company earned ($0.50) earnings per share. On average, analysts expect Apricus Biosciences to post $-0.79 EPS for the current fiscal year and $0.37 EPS for the next fiscal year.

Apricus Biosciences, Inc (APRI) opened at 1.12 on Wednesday. Apricus Biosciences, Inc has a 12 month low of $0.86 and a 12 month high of $4.94. The company’s 50-day moving average price is $1.07 and its 200 day moving average price is $1.73. The company has a market capitalization of $14.30 million, a price-to-earnings ratio of 2.52 and a beta of 0.51.

Several analysts have issued reports on APRI shares. Zacks Investment Research lowered shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Rodman & Renshaw started coverage on shares of Apricus Biosciences in a research report on Wednesday, April 26th. They set a “buy” rating for the company.

ILLEGAL ACTIVITY WARNING: “Apricus Biosciences, Inc (NASDAQ:APRI) to Release Earnings on Wednesday” was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/26/apricus-biosciences-inc-nasdaqapri-to-release-earnings-on-wednesday.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Earnings History for Apricus Biosciences (NASDAQ:APRI)

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.